EXEL vs MRNA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Jun 17, 2026
EXEL
MRNA
Investment Advisor Scores
MRNA
Jun 17, 2026AI Analyst Insights
Detailed Metrics Comparison
| Metric | EXEL | MRNA | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 16.8067 | 23.0415 | EXEL |
| PEG Ratio | 2.2685 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 10.0% | 260.2% | MRNA |
| Earnings Growth | 43.6% | -85.1% | EXEL |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 63.1/100 | 63.8/100 | MRNA |
| Profit Margin | 35.1% | -143.6% | EXEL |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
| Implied Volatility | N/A | N/A | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | BUY | BUY | Tie |